



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
19.01.2022 Bulletin 2022/03

(45) Date of publication and mention
of the grant of the patent:
08.09.2021 Bulletin 2021/36

(21) Application number: **16869342.2**

(22) Date of filing: **25.11.2016**

(51) International Patent Classification (IPC):
C07D 471/04^(2006.01) A61K 31/4985^(2006.01)
A61P 25/00^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07D 471/04; A61K 31/165; A61K 31/197;
A61K 31/4985; A61P 25/00

(86) International application number:
PCT/US2016/063779

(87) International publication number:
WO 2017/091818 (01.06.2017 Gazette 2017/22)

(54) **TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS**

TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ON ABKÖMMLINGE ALS COMT-HEMMENDE VERBINDUNGEN ZUR BEHANDLUNG NEURODGENERATIVER ERKRANKUNGEN

DÉRIVÉS DE TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES EN TANT QU'INHIBITEURS DE COMT POUR LE TRAITEMENT DES MALADIES NEURODEGENERATIVES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **25.11.2015 US 201562260067 P**

(43) Date of publication of application:
03.10.2018 Bulletin 2018/40

(73) Proprietor: **Lieber Institute Inc.**
DBA Lieber Institute For Brain Development
Baltimore, Maryland 21205 (US)

(72) Inventors:
• **BARROW, James**
Arnold, Maryland 21012 (US)
• **ERNST, Glen**
Bear, Delaware 19701 (US)
• **SWINNEN, Dominique**
1420 Braine l'Alleud (BE)
• **MONTEL, Florian**
88487 Meitingen (DE)

• **DEFAYS, Sabine**
1480 Tubize (BE)
• **HUANG, Yifang**
Lansdale, PA 19446 (US)
• **DE LÉON, Pablo**
Baltimore, MD 21230 (US)
• **POSLUSNEY, Michael Steven**
Owings Mills, MD 21117 (US)

(74) Representative: **Hoffmann Eitle**
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

(56) References cited:
WO-A1-2005/016344 WO-A1-2011/109254
US-A1- 2011 117 192 US-A1- 2013 197 219

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- SCOTT T. HARRISON ET AL: "Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT)", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 3, 26 January 2015 (2015-01-26), pages 318-323, XP055575950, ISSN: 1948-5875, DOI: 10.1021/ml500502d